Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 6

1.

Glycemic control and weight changes in patients with type 2 diabetes intensified to three insulin regimens after therapeutic failure to exenatide.

Buysschaert M, Paris I, Selvais P, Oriot P, Preumont V; UCL Exenatide Group.

Acta Clin Belg. 2012 Jul-Aug;67(4):250-4.

PMID:
23019799
[PubMed - indexed for MEDLINE]
2.

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.

Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Review.

PMID:
20646668
[PubMed - indexed for MEDLINE]
Free Article
3.

Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus.

Iltz JL, Baker DE, Setter SM, Keith Campbell R.

Clin Ther. 2006 May;28(5):652-65. Review.

PMID:
16861088
[PubMed - indexed for MEDLINE]
4.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
[PubMed - indexed for MEDLINE]
5.

Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes.

Schnabel CA, Wintle M, Kolterman O.

Vasc Health Risk Manag. 2006;2(1):69-77. Review.

PMID:
17319471
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.

Ilag LL, Kerr L, Malone JK, Tan MH.

Clin Ther. 2007 Jun;29(6 Pt 1):1254-70. Review.

PMID:
18036388
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk